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Introduction: Liver transplantation is a gold standard treatment for intractable liver diseases. Because of the shortage
of donor organs, alternative therapies have been required. Due to their potential to differentiate into a variety of
mature cells, stem cells are considered feasible cell sources for liver regeneration. Stem cells from human exfoliated
deciduous teeth (SHED) exhibit hepatogenic capability in vitro. In this study, we investigated their in vivo capabilities of
homing and hepatocyte differentiation and therapeutic efficacy for liver disorders in carbon tetrachloride (CCl4)-induced
liver fibrosis model mice.
Methods: We transplanted SHED into CCl4-induced liver fibrosis model mice through the spleen, and analyzed the
in vivo homing and therapeutic effects by optical, biochemical, histological, immunological and molecular biological
assays. We then sorted human leukocyte antigen-ABC (HLA-ABC)-positive cells from primary CCl4-damaged recipient
livers, and analyzed their fusogenicity and hepatic characteristics by flow cytometric, genomic DNA, hepatocyte-specific
gene assays. Furthermore, we examined the treatment effects of HLA-positive cells to a hepatic dysfunction by a
secondary transplantation into CCl4-treated mice.
Results: Transplanted SHED homed to recipient livers, and expressed HLA-ABC, human hepatocyte specific
antigen hepatocyte paraffin 1 and human albumin. SHED transplantation markedly recovered liver dysfunction
and led to anti-fibrotic and anti-inflammatory effects in the recipient livers. SHED-derived HLA-ABC-positive cells
that were sorted from the primary recipient liver tissues with CCl4 damage did not fuse with the host mouse liver
cells. Sorted HLA-positive cells not only expressed human hepatocyte-specific genes including albumin, cytochrome
P450 1A1, fumarylacetoacetase, tyrosine aminotransferase, uridine 5′-diphospho-glucuronosyltransferase, transferrin
and transthyretin, but also secreted human albumin, urea and blood urea nitrogen. Furthermore, SHED-derived
HLA-ABC-positive cells were secondary transplanted into CCl4-treated mice. The donor cells homed into secondary
recipient livers, and expressed hepatocyte paraffin 1 and human albumin, as well as HLA-ABC. The secondary
transplantation recovered a liver dysfunction in secondary recipients.
Conclusions: This study indicates that transplanted SHED improve hepatic dysfunction and directly transform into
hepatocytes without cell fusion in CCl4-treated mice, suggesting that SHED may provide a feasible cell source for liver
regeneration.* Correspondence: taguchi@pedsurg.med.kyushu-u.ac.jp
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Hepatic fibrosis is a severe chronic condition that occurs
as a result of various congenital and acquired hepatic dis-
orders, including viral, drug-induced, cholestatic, meta-
bolic, and autoimmune diseases. Cirrhosis, the most
advanced stage of hepatic fibrosis, usually progresses to
hepatocellular carcinoma, resulting in liver failure without
the liver’s usual self-regenerative capability. Unfortunately,
current pharmaceutical and immunological treatments are
unable to cure patients with hepatic fibrosis and/or cirrho-
sis. Liver transplantation is therefore the only treatment
with clinical success. However, few patients benefit from
organ grafting because of high medical expenses, the
long-term wait for a donor liver, organ rejection, and com-
plications [1]. Hepatocyte transplantation as an alternative
is also associated with a limited cell supply and minimal
engraft efficacy [2]. Another alternative therapy is there-
fore required urgently for hepatic fibrosis and/or cirrhosis.
A concept of stem cell-based tissue engineering and re-
generative medicine is expected to provide novel and
promising therapeutics for refractory liver diseases [3].
Human mesenchymal stem cells (MSCs) exhibit self-
renewal and multipotency into a variety of mature cells,
including hepatocytes [4]. Human MSCs have been identi-
fied in a variety of human tissues, including bone marrow
[5], adipose tissue [6], umbilical cord blood [7], amniotic
fluid stem cells [8], and dental pulp tissue [9]. Recent
studies also evaluate immunomodulatory effects of MSCs
[10]. MSCs are therefore considered a feasible cell source
for tissue engineering and regenerative medicine [11].
Some clinical phase I, I/II, and II trials have demonstrated
that human MSC transplantation recovers hepatic func-
tion in liver cirrhosis patients [12–14], indicating that
human MSCs might be a promising candidate for treat-
ments of liver dysfunction.
Stem cells from human exfoliated deciduous teeth
(SHED) are a major focus area in tissue engineering and
regenerative medicine. SHED are discovered in remnant
dental pulp tissues of human exfoliated deciduous teeth,
and share MSC characteristics, including fibroblastic fea-
tures, clonogenicity, cell surface antigen expression, cell
proliferative capacity, and multidifferentiation potency
[15]. SHED also modulate immune responses of interleu
kin-17-producing helper T (Th17) cells, regulatory T
cells (Tregs), and dendritic cells [16, 17]. Recent studies
have evaluated the latent potential of SHED in tissue en-
gineering for bone regeneration [18, 19] and cell-based
therapy for a variety of refractory systemic diseases,
including systemic lupus erythematous, spinal cord injury,
Parkinson’s disease, and diabetes [16, 20–22]. Further-
more, cryopreservation of dental pulp tissues from human
deciduous teeth has succeeded [23].
Accumulating evidence has demonstrated that a var-
iety of human MSCs, including bone marrow-derived,adipose tissue-derived, umbilical cord blood-derived,
and Wharton’s jelly-derived MSCs, are capable of differ-
entiating into hepatocyte-like cells in vivo in animal
models of hepatic failure [24–26]. Advanced tissue
engineering techniques accelerate a transdifferentiation
ability of human MSCs into hepatocytes [27, 28]. In
comparison with other human tissues, exfoliated de-
ciduous teeth offer significant advantages of less ethical
controversies and readily accessible source, easy and
minimally invasive collection, and retain high stem cell
potential such as cell proliferation, multipotency, and
immunomodulatory functions [14–16], even after cryo-
preservation [23]. Recently, many investigators have
investigated a SHED bank for allogenic cell therapy, as
well as autologous cell therapy [23, 29, 30]. Exfoliated
deciduous teeth might therefore be a feasible cell
source for MSC-based therapy for both pediatric and
adult patients with liver dysfunction.
Although SHED are known to be capable of differenti-
ating into hepatocyte-like cells in vitro [31], they have
not been evaluated for their in vivo hepatogenic capacity
or therapeutic efficacy in liver disorders. In this study,
we reveal that SHED transplantation recovers the liver
dysfunction of carbon tetrachloride (CCl4)-treated mice.
The engrafted SHED convert directly into human
hepatocyte-like cells without fusion in fibrous livers of
CCl4-treated mice. Furthermore, these in vivo SHED-
converted hepatocyte-like cells participate in the hepatic
recovery via both direct (tissue replacement) and indir-
ect (anti-fibrotic and anti-inflammatory effects) integra-
tion in CCl4-injured mouse livers.
Methods
Ethics statement and human subjects
Human samples were collected as discarded biological/
clinical samples from healthy pediatric donors (5–7
years old) in the Department of Pediatric Dentistry of
Kyushu University Hospital, Fukuoka, Japan. Proce-
dures using human samples were conducted in accord-
ance with Declaration of Helsinki, and were approved
by Kyushu University Institutional Review Board for
Human Genome/Gene Research (Protocol Number:
393-01). Written informed consent was obtained from
each parent on behalf of the child donors. All animal
experiments were approved by Institutional Animal
Care and Use Committee of Kyushu University (Proto-
col Number: A21-044-1).
Isolation and culture of SHED
Isolation and culture of SHED were performed according
to our previous reports [16, 23]. The detailed method is
described in Additional file 1. To confirm whether our
isolated cells were MSCs, the obtained passage 3 (P3) cells
were assessed by a flow cytometric analysis as described
Yamaza et al. Stem Cell Research & Therapy  (2015) 6:171 Page 3 of 16previously [16]. The P3 cells were also cultured under
osteogenic, chondrogenic, and adipogenic conditions as
described previously [23]. The P3 cells were positive for
CD146, CD73, CD105, and CD90, but negative for
hematopoietic markers (CD34, CD45, CD14, and CD11b)
(Figure S1A in Additional file 2). The P3 cells also exhib-
ited multipotency into three types of classical mesenchy-
mal lineage cells (Figure S1B–G in Additional file 2).
These phenotypes indicated that our isolated SHED ful-
filled minimal and standard criteria for MSCs [32]. The P3
cells were therefore used for further experiments in this
study.
Chronic liver fibrosis model in mice
A mixture of CCl4 (0.5 ml/kg body weight; Wako Pure
Chemicals, Osaka, Japan) and olive oil (1:4 volume/volume;
Wako Pure Chemicals) was injected intraperitoneally into
C57BL/6J mice (male, 8 weeks old; Kyudo, Tosu, Japan)
twice a week during this experimental period (see Fig. 1a).a
d e
b
Fig. 1 SHED differentiate into human hepatocyte-like cells in recipient li
transplantation in mice. C57BL/6 mice intraperitoneally received CCl4 (0.
the treatment, SHED (1 × 106) were transplanted into the CCl4-treated m
as the control for the transplantation. b In vivo monitoring of transplant
(24h) after the infusion. Dorsal position. c Enzyme-linked immunosorbent assa
transplanted SHED in recipient livers. Immunohistochemistry with anti-human
Representative images. d Counterstaining with hematoxylin. The human
Immunopositive area shown as the ratio to e the total area or f the fibro
significance. Graph bars show mean ± SD. Control, olive oil-injected group; CC
group. Ab antibody, CCl4 carbon tetrachloride, HLA human leukocyte antigen,Age-matched and sex-matched mice injected with olive oil
(Wako Pure Chemicals) were used as controls for primary
(n = 5) and secondary (n = 5) transplantation.
Primary transplantation of SHED
One million SHED (P3) suspended in 100 μl phosphate-
buffered saline (PBS) were intrasplenically transplanted
into mice treated with CCl4 for 4 weeks (n = 5) (Fig. 1a).
As a control, 100 μl PBS were infused intrasplenically
into mice treated with CCl4 for 4 weeks (n = 5). The
mice continuously received CCl4 twice a week for an
additional 4-week treatment after the transplantation.
All of the animals were sacrificed to harvest the livers
and peripheral blood.
Colorimetric analysis and enzyme-linked immunosorbent
assay of mouse serum and liver samples
Serum alkaline phosphatase (ALP), alanine aminotransfer-
ase (ALT), aspartate aminotransferase (AST), and totalf
c
vers of CCl4-treated mice. a Schema of CCl4 treatment and SHED
5 ml/kg) or olive oil only twice a week (red arrows). Four weeks after
ice through the spleen. Phosphate-buffered saline (PBS) was infused
ed DiR-labeled SHED in CCl4-treated mice 1 hour (1h) or 24 hours
y of human albumin (hALB) in the recipient serum. d–f Distribution of
HLA-ABC, anti-hepatocyte paraffin 1 (Hep Par1), or anti-hALB antibody.
HLA-ABC, hepatocyte paraffin 1, or hALB antibody positive area.
us area. c, e, f n = 5 for all groups. *P <0.05 and ***P <0.005. ns no
l4, CCl4-treated group; CCl4 + SHED, SHED-transplanted CCl4-treated
SHED stem cells from human exfoliated deciduous teeth
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plate spectrophotometer (Thermo Scientific, Waltham,
MA, USA) using commercially available kits according
to the manufacturer’s protocol: ALP, LabAssay ALP Kit
(Wako Pure Chemicals); ALT and AST, Transaminase
CII-Test Kit (Wako Pure Chemicals); and total bilirubin,
Bilirubin QuantiChrom Assay Kit (BioAssay Systems,
Hayward, CA, USA). Liver hydroxyproline contents were
measured with a Multiskan GO microplate spectropho-
tometer (Thermo Scientific) using a Hydroxyproline Assay
Kit (Biovision, Milpitas, CA, USA). Serum mouse interleu-
kin (IL)-6, IL-10, IL-17, transforming growth factor β1
(TGF-β1), and tumor necrosis factor alpha (TNFα) were
also measured using Quantikine ELISA kits (R&D Sys-
tems, Minneapolis, MN, USA).
Histological and immunohistochemical analyses of mouse
liver tissues
Tissue preparation, Masson’s trichrome staining, and im-
munohistochemical staining were performed as described
in Additional file 1. The sections were observed under an
Axio Imager M2 (Zeiss, Oberkochen, Germany) for mor-
phometric assays, and five representative images from
each mouse were selected randomly and were used to
measure a percentage of fibrous tissue area or primary
antibody-positive area using ImageJ software (NIH,
Bethesda, MD, USA). Trichrome stained sections were an-
alyzed to score the amount of liver disease using Ishak
scoring [33].
Double immunofluorescence
Double immunofluorescent staining was performed as
described in Additional file 1. The sections were observed
under an Axio Imager M2 (Zeiss).
Quantitative real-time RT-PCR assay
Total RNAs were extracted and treated as described in
Additional file 1. Real-time RT-PCR was subsequently
performed using a TaqMan Gene Expression Master
Mix (Applied Biosystems, Foster City, CA, USA) and
target TaqMan probes (Applied Biosystems) (Table S1
in Additional file 3) with a Light Cycler 96 (Roche,
Indianapolis, IN, USA). 18S ribosomal RNA was used
for normalization.
Sorting of HLA-ABC-positive or HLA-negative cells from
liver tissues of CCl4-treated mice transplanted with SHED
Livers of primary recipients (n = 5) were perfused with
collagenase type H (0.1 mg/ml; Worthington Biochemi-
cals, Lakewood, NJ, USA) in PBS and gently dispersed.
Single suspended cells were stained with phycoerythrin
(PE)-conjugated anti-human leukocyte antigen (HLA)-
ABC (eBioscience, San Diego, CA, USA) and magnetic
bead-conjugated anti-PE antibodies (Miltenyi Biotec,Bergisch Gladbach, Germany). They were magnetically
sorted using a MidiMACS separator (Miltenyi Biotec)
equipped with a LD column (Miltenyi Biotec), and the
positive and negative fractions were collected separately.
Cell fusion assay in HLA-positive cells
Magnetically sorted HLA-ABC-positive and HLA-negative
fractions were stained with PE-conjugated anti-human
major histocompatibility complex (MHC) class I HLA-
ABC (eBioscience) and allophycocyanin (APC)-conju-
gated anti-mouse major MHC class I H-2Kb (eBioscience)
antibody. The cells were measured with a FACS Verse
flow cytometer (BD Biosciences, San Jose, CA, USA),
and were analyzed by BD FACS Suite software (BD
Biosciences).
Human-specific genome assay in HLA-positive cells
Genomic DNA was extracted from HLA-ABC-positive
and HLA-negative fractions using a DNeasy Blood and
Tissue Kit (Qiagen, Venlo, the Netherlands), and was
amplified with a T-100 thermal cycler (Bio-Rad, Hercules,
CA, USA) using Quick Taq HS DyeMix (TOYOBO,
Osaka, Japan) and specific primer pairs by PCR assay.
The specific primer pairs are presented in Table S2 in
Additional file 3.
Characterization of HLA-positive cells as human
hepatocytes
Sorted HLA-ABC-positive cells were cultured with Iscove’s
modified Dulbecco’s medium (Invitrogen, Waltham, MA)
supplemented with epidermal growth factor (EGF) (20 ng/
ml; PeproTech, Rocky Hill, NJ, USA), fibroblast growth
factor 2 (FGF2) (10 ng/ml; PeproTech), and hepatocyte
growth factor (HGF) (20 ng/ml; PeproTech). Some cultures
were stained with toluidine blue.
Expression of human hepatocyte-specific genes in
HLA-positive cells was analyzed by RT-PCR with a T-
100 thermal cycler (Bio-Rad) as described previously
[16, 23]. The specific primer pairs are presented in
Table S2 in Additional file 3. HepG2 cells (Riken, Tsukuba,
Japan) were used as positive control. Human albumin and
urea in the culture supernatants of HLA-positive cells
were measured with a Multiskan GO microplate spectro-
photometer (Thermo Scientific) using a Human Albumin
ELISA Quantitation Set (AssayPro, St Charles, MO, USA)
and a QuantiChrom Urea Assay Kit (Bioassay Systems),
respectively.
Secondary transplantation of HLA-ABC-positive or HLA-
negative cells sorted from liver tissues of CCl4-treated
mice with primary transplantation of SHED
To understand whether SHED-derived in vivo-converted
hepatocyte-like cells express hepatic function in vivo, we
performed a secondary transplantation of the SHED-
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CCl4-damaged mice. The mice (n = 5 each) were treated
with CCl4 for 4 weeks, and were then transplanted with
1 million HLA-positive or HLA-negative cells via the
spleen and continuously received CCl4 twice a week for
an additional 4-week treatment after the transplantation
(shown in Fig. 6a). We also used CCl4-treated mice and
nontreated mice without the cell transplant (n = 5 each).
Finally, the peripheral blood serum and liver samples
were harvested, and used for further experiments.
In vivo monitoring of transplanted cells
Cells were labeled with near-infrared (NIR) lipophilic
carbocyanine membrane dye, 1,1-dioctadecyl-3,3,3,3-
tetramethylindotricarbocyanine iodide (DiR). The cells
(1 × 107 in 10 ml PBS) were incubated with XenoLight
DiR NIR Fluorescent Dye (10 μg/ml; Perkin Elmer,
Waltham, MA, USA) for 30 minutes at 37 °C, and were
then washed twice with PBS. In vivo optical imaging
was performed to detect the transplanted cells. The
labeled cells (1 ×106 in 100 μl PBS) were infused intras-
plenically into CCl4-pretreated mice (n = 5). As a con-
trol for cell transplantation, nonlabeled SHED (1 × 106
in 100 μl PBS) were infused into CCl4-pretreated mice
via the spleen (n = 5). Ventral images were captured
from each animal group after 1 or 24 hours under an
optical in vivo imaging system IVIS Lumina III (Perkin
Elmer), and were analyzed using living image software
(Perkin Elmer).
Statistical analysis
Statistical results are expressed as mean ± standard devi-
ation (SD). Multiple group comparison was analyzed by
one-way repeated-measures analysis of variance followed
by the Tukey post hoc test using PRISM 6software
(GraphPad, Software, La Jolla, CA, USA). P <0.05 was
considered significant.
Results
Transplanted donor SHED are capable of homing and
differentiating into human hepatocyte-like cells in recipient
livers of CCl4-injured mice
Mouse livers showed fibrosis after 4 weeks of treatment
with CCl4 (data not shown). To address a therapeutic
potential of SHED for liver disorders, SHED (1 × 106 per
mouse) were intrasplenically injected into mice that had
been treated with CCl4 for 4 weeks (Fig. 1a). We first
investigated whether transplanted SHED were capable of
engrafting in the CCl4-treated mouse liver parenchyma.
DiR-labeled SHED were infused into a spleen of CCl4-
treated mice. In vivo imaging demonstrated that the
intensity of DiR was detected on the liver, as well as the
spleen, 1 hour after transplantation (Fig. 1b). The signals
were enhanced in both the liver and spleen 24 hoursafter transplantation (Fig. 1b). Non-CCl4-treated mice
and non-SHED-infused CCl4-treated mice expressed no
signal at 1 and 24 hours after transplantation (Fig. 1b).
By the carboxyfluorescein diacetate succinimidyl ester
(CFSE)-labeled cell trace technique, CFSE-labeled SHED
were detected in CCl4-damaged mouse liver 1 day after
the transplantation (Figure S2 in Additional file 2). Our
immunohistochemical analysis also detected positive
immunoreactions to anti-HLA-ABC antibody in spleens
of CCl4-damaged mice, but negative immunoreaction to
anti-HLA-ABC antibody in spleens of CCl4-damaged
mice (Figure S3B, C in Additional file 2). In addition, no
immunoreaction to anti-HLA-ABC and anti-hepatocyte
paraffin 1 antibodies was detected in the kidneys and
lungs of CCl4-damaged mice (Figure S3B, C in Additional
file 2). These findings suggested that DiR-labeled SHED
were recruited to CCl4-damaged liver from the trans-
planted site, the spleen.
To confirm in vivo homing of transplanted SHED, per-
ipheral blood serum and liver tissues were harvested
from SHED-transplanted CCl4-treated mice, nontrans-
planted CCl4-treated mice, and non-CCl4-treated mice
in week 8. Enzyme-linked immunosorbent assay (ELISA)
detected human albumin in the serum of SHED-
transplanted CCl4-treated mice, but not in both nontrans-
planted CCl4-treated mice and non-CCl4-treated mice
(Fig. 1c). An immunohistochemical assay demonstrated
that HLA-ABC-positive cells with a cuboidal shape were
found in the interlobular and portal areas (Fig. 1d), which
corresponded to the fibrotic region in CCl4-injured liver
tissues (Fig. 2b). The HLA-ABC-positive cells occupied
16.27 ± 10.17 % of the recipient liver tissues (Fig. 1e).
Furthermore, to verify whether the transplanted donor
cells differentiated into human hepatocytes in recipient
livers, immunohistochemical assay was performed using
human hepatocyte-specific hepatocyte paraffin 1 and
human albumin-specific antibodies. The hepatocyte
paraffin 1-positive and human albumin-positive cells
were distributed in interlobular and portal areas of the
recipient livers similar to the HLA-ABC-positive cells
(Fig. 1d), and were expressed in 11.39 ± 4.58 % and
10.73 ± 6.18 % of the recipient liver tissues, respectively
(Fig. 1e). The hepatocyte paraffin 1-positive and human
albumin-positive areas tended to be less than the HLA-
ABC-positive area, but not significant (Fig. 1e). No
immunoreactivity against HLA-ABC, hepatocyte paraf-
fin 1, or human albumin was found in the liver tissue
of nontransplanted CCl4-induced mice (Fig. 1d) or in
control mice (data not shown). No immunoreactivity
against HLA-ABC, hepatocyte paraffin 1, or human
albumin is found for liver sections treated with nonim-
mune IgG instead of the primary antibodies (Figure S4
in Additional file 2). Positive immunoreaction to anti-
HLA-ABC, anti-hepatocyte paraffin 1, and anti-human
Fig. 2 SHED ameliorate the hepatic dysfunction in recipient livers of CCl4-treated mice. a Serum assays for the hepatic function. b–f Liver fibrosis
assays. b Representative images of livers. Masson Trichrome staining. Arrowheads, fibrous deposition. c Fibrotic area. d Fibrotic score. e
Hydroxyproline assay in recipient livers. f Real-time RT-PCR analysis of mouse type I collagen (mCola1) mRNA in recipient livers. a, c–f n = 5 for
all groups. Control, olive oil-injected group; CCl4, CCl4-treated group; CCl4 + SHED, SHED-transplanted CCl4-treated group. *P <0.05 and ***P <0.005. ns
no significance. Graph bars show the mean ± SD. ALT alanine aminotransferase, ALP alkaline phosphatase, AST aspartate aminotransferase, CCl4 carbon
tetrachloride, SHED stem cells from human exfoliated deciduous teeth
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cells of human liver tissues (Figure S5 in Additional file 2),
but human liver tissues expressed negative immunoreac-
tion to nonimmune mouse IgG (Figure S5 in Additional
file 2). These results indicated that donor SHED showed
an in vivo capacity of engrafting and differentiating into
human hepatocyte-like cells in the recipient livers of
CCl4-injured mice.
SHED transplantation decreased CCl4-induced chronic
fibrosis in mouse livers
To address whether SHED have therapeutic potential
for liver disorders, SHED-transplanted CCl4-treatedmice, as well as nontransplanted (PBS-injected) CCl4-
treated mice, received continuous CCl4 injections for
an additional 4 weeks (Fig. 1a). In week 8, the nontrans-
planted mice showed severe fibrous liver dysfunction
(Fig. 2). A biochemical serum assay revealed that SHED
transplantation markedly recovered the damaged liver
functions (Fig. 2a). Masson trichrome staining showed
that SHED transplantation reduced CCl4-enhanced
fibrous deposition in the liver (Fig. 2b, c). The fibrous
tissue area occupied 5.98 ± 1.35 %, 18.16 ± 3.36 %, and
8.89 ± 3.07 % of the recipient liver tissues in control
mice, nontransplanted CCl4-treated mice, and SHED-
transplanted CCl4-treated mice, respectively (Fig. 2c).
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0 ± 0, 3.60 ± 0.43, and 1.67 ± 0.41 of the recipient liver
tissues in control mice, nontransplanted CCl4-treated
mice, and SHED-transplanted CCl4-treated mice, re-
spectively (Fig. 2d). Colorimetric and real-time PCR
assays revealed that SHED transplantation significantly
reduced the hydroxyproline content and collagen pro-
duction in the CCl4-damaged liver tissues (Fig. 2e, f ).
Interestingly, HLA-ABC, hepatocyte paraffin 1, or
human albumin-positive cells captured a similar area to
the fibrous deposit region in the liver of nontrans-
planted CCl4-treated mice (Fig. 1d–f ). To confirm the
in vivo hepatogenic differentiation capacity and thera-
peutic efficacy of SHED in recipient CCl4-injured livers,
we infused pediatric human gingival fibroblasts as a
control for SHED transplantation in CCl4-treated mice
(Figure S6A in Additional file 2). Immunohistochemical
assay showed that no HLA-ABC, hepatocyte paraffin 1,
or human albumin-positive human cells were detected
in the recipient CCl4-damaged liver tissues (Figure S6B
in Additional file 2). Biochemical assays demonstrated
that human gingival fibroblast infusion did not recover
the impaired hepatic function in CCl4-injected mice
(Figure S6C in Additional file 2). Taken together, these
findings indicated that SHED transplantation suppressed
CCl4-enhanced fibrous deposition in the liver of CCl4-
treated mice, and suggested that SHED directly/spon-
taneously transdifferentiated into human hepatocytes in
CCl4-damaged livers.
Activation of hepatic stellate cells is a crucial event re-
quired to initiate and promote hepatic fibrosis, followed
by producing and remodeling of type I collagen by
matrix metalloproteinases (MMPs) and tissue inhibitors
of metalloproteinase (TIMPs) [34]. We therefore exam-
ined the kinetics of activated hepatic stellate cells after
SHED transplantation in recipient livers 8 weeks after
the first CCl4 injection. Immunohistochemical analysis
indicated that SHED transplantation decreased the area
of alpha smooth muscle actin (αSMA)-positive cells,
which indicated activated hepatic stellate cells, in the
CCl4-injured liver tissues (Fig. 3a, b). A real-time PCR
assay also demonstrated that SHED transplantation sig-
nificantly reduced the expression of αSMAmRNA (Fig. 3c)
and markedly suppressed CCl4-induced MMP2, MMP9,
TIMP1, and TIMP2 mRNA expression (Fig. 3d) in the
injured livers.
Kupffer cells and T lymphocytes and the fibrotic and
inflammatory cytokines, such as TGF-β, TNFα, IL-6, and
IL-17, produced by them are also involved in the pro-
gression of hepatic fibrosis and activation of hepatic stel-
late cells [34, 35]. By immunohistochemical assays, CCl4
treatment markedly induced infiltration of F4/80-posi-
tive and CD3-positive cells in the liver, which indicate
Kupffer cells and/or macrophages and T lymphocytes,respectively, compared with non-CCl4-treated livers
(Fig. 4a–c). SHED transplantation suppressed the altered
distribution of F4/80-positive and CD3-positive cells in
the CCl4-treated livers (Fig. 4a–d). Further histochemical
analysis demonstrated that SHED transplantation did
not induce any heavy infiltration of lymphocyte-like
cells, and did not cause any severe change of structural
components in other tissues such as the kidneys, lungs,
and spleens of CCl4-treated mice with SHED (Figure S3A
in Additional file 2). Real-time PCR and ELISA studies
demonstrated that SHED transplantation reduced the
expression of TGF-β1, TNFα, and IL-6 mRNAs in the
CCl4-induced fibrous livers (Fig. 3e), and suppressed
the elevation of IL-6, TGF-β, and TNFα in the serum
of CCl4-treated mice (Fig. 4e). SHED transplantation re-
duced the proinflammatory IL-17 expression and recov-
ered the decreased anti-inflammatory IL-10 expression in
the CCl4-treated livers (Fig. 4e). Taken together, these
findings indicated that transplanted SHED might exhibit
anti-fibrotic and anti-inflammatory effects against liver fi-
brosis by suppressing the activation of hepatic stellate
cells, Kupffer cells/macrophages, and T cells.
Donor SHED are capable of differentiating into human
hepatocyte-like cells without fusion in CCl4-injured mouse
livers
Transplanted bone marrow cells fuse with host hepato-
cytes in damaged livers [36, 37], but bone marrow MSCs
differentiate into hepatocytes without cell fusion in
recipients [24]. Using dual immunofluorescent staining
using human specific antibodies to hepatocyte paraffin 1
and albumin, we demonstrated that double positive cells
to hepatocyte paraffin 1 and human albumin were found
in liver tissues of CCl4-injured mice with SHED trans-
plantation (Fig. 5a). However, it was unclear whether the
double positive cells were fused with host cells or not; a
possibility of cell fusion between donor SHED and
recipient hepatocytes remained. To evaluate whether the
in vivo converted SHED-derived human hepatocyte-like
cells were fused with host hepatocytes, we isolated
human cells from recipient livers of SHED-transplanted
CCl4-treated mice (Figure S7 in Additional file 2). Pan-
liver cells were isolated from the recipient livers with the
collagenase digestion method, and stained with anti-
HLA-ABC antibody. The HLA-ABC-positive cells were
magnetically sorted to collect separately from HLA-
ABC-negative cells. Flow cytometric analysis confirmed
that the HLA-ABC-positive fraction was 95.5 ± 4.43 %
positive to HLA-ABC, but negative to mouse H-2Kb
(Fig. 5b). Double positive cells were also not detected
(Fig. 5b). On the other hand, the HLA-ABC-negative
fraction was 96.3 ± 5.68 % positive to H-2Kb, but 0 %
to HLA-ABC (data not shown). The HLA-ABC-positive
cells maintained under EGF, FGF2, and HGF
a b c
d e
Fig. 3 SHED transplantation suppresses the activation of hepatic stellate cells in livers of CCl4-treated mice. a–c Expression of alpha smooth
muscle actin (αSMA). a Immunohistochemical staining with anti-αSMA antibody in recipient livers. b αSMA-positive area. c Real-time RT-PCR
analysis of mouse αSMA (mαSMA) mRNA. d, e Real-time RT-PCR analysis. d Expression of mouse MMP9 and MMP2 (mMMP9, mMMP2) and
mouse TIMP1 and TIMP2 (mTIMP1, mTIMP2) mRNA in recipient livers. e Expression of mouse interleukin-6 (mIL-6), mouse transforming growth
factor β1 (mTGFβ1), and mouse tumor necrosis factor alpha(mTNFα) mRNA in recipient livers. b–e n = 5 for all groups. *P <0.05, **P <0.01, and
***P <0.005. ns no significance. Graph bars show the mean ± SD. Control, olive oil-injected group; CCl4, CCl4-treated group; CCl4 + SHED:
SHED-transplanted CCl4-treated group. CCl4 carbon tetrachloride, MMP matrix metalloproteinase, SHED stem cells from human exfoliated
deciduous teeth, TIMP tissue inhibitor of matrix metalloproteinase
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dishes by toluidine blue staining (Fig, 5c). A genomic
DNA assay demonstrated that a human specific gene,
Alu, was detected only in HLA-ABC-positive cells, but
not in HLA-ABC-negative cells (Fig. 5d). On the other
hand, a mouse specific gene, mpf1, was not detected in
HLA-ABC-positive cells, but was found in HLA-ABC-
negative cells (Fig. 5d). RT-PCR analysis also demon-
strated that human albumin gene was detected only in
HLA-ABC-positive cells, but not in HLA-ABC-negative
cells, while mouse albumin gene was expressed in
HLA-ABC-negative cells, but not in HLA-ABC-positive
cells (Fig. 5e). These data indicate that transplanted
SHED were directly transdifferentiated into human
hepatocytes without fusion with recipient mouse
hepatocytes.
Further RT-PCR assay demonstrated that the purified
HLA-ABC-positive cells expressed human hepatocyte-
specific genes, albumin, cytochrome P450 1A1, cytochrome
P450 3A7, fumarylacetoacetase, tyrosine aminotransferase,
uridine 5′-diphospho (UDP)-glucuronosyltransferase, trans-
ferrin, and transthyretin (Fig. 5f). However, the expression
levels of human hepatocyte-specific genes in the puri-
fied HLA-ABC-positive cells were lower whencompared with human hepatocyte cell line HepG2
(Fig. 5f). By ELISA and colorimetric assay, human albu-
min, urea, and blood urea nitrogen were detected at 4.8 ±
0.085 ng/ml, 0.47 ± 0.01 mg/dl, and 0.22 ± 0.005 mg/dl,
respectively, in the culture supernatant of HLA-positive
cells cultured with EGF, FGF2, and HGF stimulation for 3
days. Taken together, these findings indicate that SHED
might show a potential for transdifferentiating into func-
tional human hepatocytes, at least partially, without fusing
with host mouse hepatocytes in fibrotic livers of CCl4-
treated mice.
Secondary transplantation of SHED-derived human
hepatocyte-like cells purified from primary CCl4-injured
recipient livers recovered hepatic dysfunction of
CCl4-treated mice
Next we examined the homing capability of SHED-
derived in vivo-converted hepatocyte-like cells. Mice
that had been treated with CCl4 for 4 weeks under-
went secondary transplantation of purified HLA-ABC-
positive cells (1 × 106), as well as HLA-ABC-negative
cells (1 × 106), into the spleen (Fig. 6a). In vivo im-
aging analysis showed that strong intensity of DiR-labeled




Fig. 4 SHED transplantation inhibits the enhanced distribution of Kupffer cells and T cells in recipient livers of CCl4-treated mice. a–c Expression
of F4/80 and CD3 in recipient livers. Immunohistochemical staining with anti-F4/80 (a) and anti-CD3 antibodies (c). The F4/80-positive (b) and
CD3-positive (d) area. e ELISA of recipient serum. b, d, e n = 5 for all groups. *P <0.05, **P <0.01, and ***P <0.005. Graph bars show the means ±
SD. Control, olive oil-injected control group; CCl4, CCl4-treated group; CCl4 + SHED, SHED-transplanted CCl4-treated group. CCl4 carbon tetrachloride,
mIL mouse interleukin, mTGFβ1 mouse transforming growth factor β1, mTNFα mouse tumor necrosis factor alpha, SHED stem cells from human
exfoliated deciduous teeth
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hours post transplantation (Fig. 6b). Further immuno-
histochemical analysis and ELISA was performed in the
liver tissues and peripheral blood serum of CCl4-treated
mice that underwent secondary transplantation with HLA-
ABC-positive and HLA-ABC-negative cells, as well as of
nontransplanted CCl4-treated mice and nonCCl4-treated
mice, in week 8.
An immunohistochemical examination demonstrated
that HLA-ABC-positive, hepatocyte paraffin 1-positive,
and human albumin-positive cells were observed in the
interlobular and portal regions corresponding to the
fibular deposited area in liver tissues of CCl4-treated
mice that underwent secondary transplant with HLA-
ABC-positive cells 4 weeks after the primary transplant
(Fig. 6c). The HLA-ABC-positive, hepatocyte paraffin1-positive, and human albumin-positive cell areas were
23.22 ± 6.81 %, 19.31 ± 5.06 %, and 17.80 ± 4.71 % in
the secondary recipient livers (Fig. 6d). The immuno-
histochemically positive areas expressed a similar rate
to the liver fibrous area of nontransplanted CCl4-in-
jured mice (Figure S8 in Additional file 2). No immuno-
reactivity against HLA-ABC, hepatocyte paraffin 1, or
human albumin was detected in the liver tissues of
CCl4-induced mice that underwent secondary trans-
plant with HLA-ABC-negative cells (Fig. 6c) or in non-
transplanted CCl4-induced mice and non-CCl4-induced
mice (data not shown). ELISA also showed that serum
human albumin was detected in CCl4-treated mice that
underwent secondary transplant with HLA-ABC-positive
cells, but not in CCl4-treated mice that underwent




Fig. 5 SHED-derived HLA-ABC-positive cells purified from primary recipient livers of CCl4-treated mice express hepatocyte-specific genes without
host-cell fusion. a Double-immunofluorescent staining patterns for HepPar and human albumin (hALB) in CCl4-injured liver tissues transplanted
with SHED. b Flow cytometric analysis of magnetically sorted HLA-ABC-positive (HLA+) cells stained with PE-conjugated anti-human HLA-ABC and
APC-conjugated anti-mouse H-K2b antibodies. c Morphology of sorted HLA+ cells. Toluidine blue staining. d Genomic DNA assay. e RT-PCR
analysis of hALB and mouse albumin (mALB) mRNAs. f RT-PCR analysis of human hepatocyte-specific genes. ALB albumin, Alu human-specific Alu gene,
CCl4 carbon tetrachloride, CYP1A1 cytochrome P450 1A1, CYP3A7 cytochrome P450 3A7, DAPI 4′,6-diamidino-2-phenylindole, FAH fumarylacetoacetate
hydrolase, GAPDH human glyceraldehyde 3-phosphate dehydrogenase, HepG2 human hepatoma cell line, HepPar1 human hepatocyte specific
HepParaffin 1 antigen, HLA human leukocyte antigen, HLA– HLA-ABC-negative cells, mpf1 mouse-specific Pf1 gene, SHED stem cells from
human exfoliated deciduous teeth, TAT tyrosine aminotransferase, TF transferrin, TTR transthyretin, UGT1A1 uridine
5′-diphospho-glucuronosyltransferase 1A1
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mice (Fig. 6e).
To evaluate a therapeutic efficacy of SHED-derived
in vivo-converted hepatocyte-like cells, peripheral blood
serum and liver tissues were harvested from the mice in
week 8. Serum assay demonstrated that the secondary
transplantation of primary HLA-ABC-positive cells re-
covered hepatic markers of CCl4-treated mice (Fig. 7a;
Figure S9 in Additional file 2). Masson trichrome staining
and hydroxyproline content assay demonstrated that the
secondary transplantation of primary HLA-ABC-positive
cells reduced the production and deposition of fibrous
matrix (Fig. 7b–d; Figure S10A in Additional file 2). By
real-time RT-PCR, expression of mouse type I collagen
mRNA was also suppressed in the secondary recipient
liver transplanted with HLA-ABC-positive cells compared
with the nontransplanted recipient livers (Figure S10B inAdditional file 2). On the other hand, the secondary
transplantation of HLA-ABC-negative cells did not re-
store the hepatic function and fibrous tissue deposition
in CCl4-injured livers (Fig. 7; Figures S9 and S10 in
Additional file 2).
Moreover, by immunohistochemical and real-time PCR
analyses, we demonstrated that secondary transplantation
of HLA-ABC-positive cells significantly reduced the
increased αSMA expression in CCl4-injured liver tissues
(Fig. 8a–c). Further real-time PCR assay demonstrated
that the secondary transplantation of HLA-ABC-positive
cells markedly inhibited the enhanced MMP2, MMP9,
TIMP1, and TIMP2 mRNA expressions (Fig. 8d) in CCl4-
injured livers. On the other hand, the increased distribu-
tion of αSMA-positive cells and enhanced expression of
αSMA, MMP2, MMP9, TIMP1, TIMP2, TGF-β1, TNFα,
and IL-6 mRNAs were not recovered in CCl4-treated mice
a b
c d e
Fig. 6 Secondary transplanted primary HLA-ABC-positive cells home to CCl4-treated recipient livers. a Schema of secondary transplantation of
primary HLA-ABC+/HLA-ABC– cells into C57BL/6 mice. HLA-ABC+/HLA-ABC– cells (1 × 106) or phosphate-buffered saline (PBS) were infused into
the mice that had intraperitoneally received CCl4 (0.5 ml/kg) or olive oil only twice a week (red arrows). b In vivo monitoring of DiR-labeled
HLA-ABC-positive (HLA+) and HLA-negative (HLA–) cells in CCl4-treated mice 24 hours (24h) after the infusion. c, d Distribution of transplanted
HLA+ and HLA– cells in the secondary recipient livers. Immunohistochemistry with anti-human HLA-ABC (HLA-ABC), anti-hepatocyte paraffin 1 (Hep
Par1), or anti-human albumin (hALB) antibody. Representative images. c Counterstaining with hematoxylin. The human HLA-ABC, hepatocyte paraffin
1, or human albumin-positive area. d Immunopositive area shown as the ratio to the total area. e ELISA of human albumin (hALB) in the recipient
serum. c–e n = 5 for all groups. ***P <0.005. ns no significance. Graph bars show the mean ± SD. Control, olive oil-injected group; CCl4,
CCl4-treated group; CCl4 + HLA
+, HLA+ cell-transplanted CCl4-treated group; CCl4 + HLA
–, HLA– cell-transplanted CCl4-treated group. Ab
antibody, CCl4 carbon tetrachloride, HepPar1 human hepatocyte specific HepParaffin 1 antigen, HLA human leukocyte antigen
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negative cells (Fig. 8). Taken together, these findings
suggested that in vivo-generated hepatocyte-like cells in
CCl4-injured livers with SHED transplantation worked
functionally, at least partially, as human hepatocytes to
display therapeutic efficacy for CCl4-induced liver fi-
brosis [38].
Discussion
Severe shortage of donor organs is a major challenge for
liver transplantation [1]. Because of their unique capaci-
ties for homing and hepatic differentiation, MSCs and
hematopoietic stem cells have been receiving attention
as a source for cell therapy as an alternative to liver
transplantation [39]. Transplantation of isolated mature
hepatocytes has been used as an experimental therapy
for liver disease in a limited number of cases. Recently,100 cases of hepatocyte transplantation have been
reported. Clinically, hepatocyte transplants express a
proven efficiency, particularly in cases of metabolic liver
disease where reversal or amelioration of the characteristic
symptoms of the disease is easily quantified. However,
no patients are completely corrected of a metabolic
liver disease for a significant amount of time by hepato-
cyte transplantation alone [40]. MSC transplantation
[12–14], as well as hematopoietic stem cell transplant-
ation [41, 42], can successfully treat liver failure in ani-
mal models. MSCs exhibit a greater therapeutic efficacy
with regard to homing and reducing fibrosis in com-
parison with hematopoietic stem cells in injured livers
[43, 44]. In the present study, we demonstrated that
SHED transplantation improved CCl4-induced liver fi-
brosis and hepatic dysfunction via inertness of activated
hepatic stellate cells and by replacement of damaged
Fig. 7 Secondary transplantation of primary HLA-ABC-positive cells ameliorates the liver dysfunction in CCl4-treated recipient livers. a Serum
assays for the hepatic function. b–d Liver fibrosis assays. b Representative images of livers. Masson Trichrome staining. c Fibrotic area. d
Hydroxyproline assay in recipient livers. a, c, d n = 5 for all groups. ***P <0.005. ns no significance. Graph bars show the mean ± SD. Control,
olive oil-injected group; CCl4, CCl4-treated group; CCl4 + HLA
+, HLA+ cell-transplanted CCl4-treated group; CCl4 + HLA
–, HLA– cell-transplanted
CCl4-treated group. AST aspartate aminotransferase, ALT alanine aminotransferase, CCl4 carbon tetrachloride, hALB human albumin, HLA human
leukocyte antigen
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cells. These findings therefore suggest that SHED might
be a promising MSC source for liver regeneration.
The present study demonstrated that SHED trans-
plantation markedly suppressed not only the pathological
activation of hepatic stellate cells, but also the excessive
infiltration of Kupffer cells and T cells in CCl4-damaged
mouse livers. Furthermore, SHED transplantation sig-
nificantly reduced the enhanced production of fibro-
genic and inflammatory factors, such as TGF-β1, TNFα,
MMP2, MMP9, TIMP1, TIMP2, IL-6, and IL-17, and
enhanced the expression of the anti-inflammatory fac-
tor IL-10 in CCl4-induced fibrous livers. Activatedhepatic stellate cells contribute to liver fibrosis via ab-
normal production of MMP2, TIMP1, and TIMP2
through the secretion of various inflammatory cyto-
kines from Kupffer cells and T cells [34, 35]. SHED
can induce Tregs and suppress Th17 cells and mono-
cytes/dendritic cells [16, 17]. Transplanted SHED
might therefore suppress immune responses and pro-
mote anti-fibrotic regulation by affecting hepatic stel-
late cells, Kupffer cells, and T cells in CCl4-damaged
mouse livers.
We speculate that a considerable number of trans-
planted SHED might be rejected immunologically owing
to the present xenogeneic transplantation system and
Fig. 8 Secondary transplantation of primary HLA-ABC-positive cells suppresses the activation of hepatic stellate cells and induction of Kupffer cells
in livers CCl4-treated mice. a–c Expression of alpha smooth muscle actin (αSMA). a Immunohistochemical staining with anti-αSMA antibody in
recipient livers. b αSMA-positive area. c Real-time RT-PCR analysis of mouse αSMA (mαSMA) mRNA. d Real-time RT-PCR analysis of mouse MMP9
and MMP2 (mMMP9, mMMP2) and mouse TIMP1 and TIMP2 (mTIMP1, mTIMP2) mRNA in recipient livers. b–d n = 5 for all groups. *P <0.05, **P <0.01,
and ***P <0.005. ns no significance. Graph bars show the mean ± SD. Control, olive oil-injected group; CCl4, CCl4-treated group; CCl4 + HLA
+, HLA+
cell-transplanted CCl4-treated group; CCl4 + HLA
–, HLA– cell-transplanted CCl4-treated group. CCl4 carbon tetrachloride, HLA human leukocyte antigen,
MMP matrix metalloproteinase, TIMP tissue inhibitor of matrix metalloproteinase
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We also consider a possibility that donor SHED and the
differentiated hepatocytes, as well as recipient hepatocytes,
might be damaged by chronic CCl4 stimuli. On the con-
trary, a result that donor SHED survived to differentiate
into human hepatocytes in CCl4-injured liver tissues sug-
gests that the donor cells maintained higher toxic resistance
compared with recipient cells, and supports that donor
SHED, at least partially, showed a tolerance to host im-
mune response, even under nonimmunosuppressive condi-
tion, in immunocompetent mice. Furthermore, SHED
transplantation did not induce any heavy infiltration of
lymphocyte-like cells, as well as any change of structural
components, in other tissues including the kidney, lung,
and spleen of CCl4-treated mice. On the other hand,
SHED transplantation suppressed the immune reaction in
CCl4-treated mice. These findings support that donorSHED did not cause any graft versus host disease-like re-
action. Taken together, these findings suppose that SHED
might exhibit safe immunology in the present xenogeneic
transplantation system. Less HLA-DR expression and ac-
tive immunomodulatory function of SHED may support a
low immunogenicity and can acquire immune tolerance
in vivo [16, 45]. Further study will be necessary to confirm
the immunological safety of SHED as a donor for allogenic
transplantation, as well as autologous transplantation, for
liver patients.
The liver is a site of hematopoiesis in the fetus, so
bone marrow hematopoietic stem cells have been con-
sidered an origin for hepatocytes in adults [46, 47].
Transplanted hematopoietic stem cells fuse with host
hepatic cells to repopulate the liver as functional hepato-
cytes [36, 37]. On the other hand, a nonfusion origin
of human hepatocytes was proposed in mouse liver
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Engrafted bone marrow MSCs directly transdifferen-
tiated into hepatocytes without cell fusion in rat livers
[24]. Therefore, whether donor human cells fuse with
recipient hepatic cells in mouse liver has not yet been
fully understood. The presented three different approaches
with a cell sorting technique of MHC class I antigen
HLA-ABC-expressed human cells from the recipient
mouse liver were carried out to evaluate the possibility of
fusion between donor human MSCs and recipient murine
hepatocytes. By flow cytometric analysis using human and
mouse specific antibodies against MHC class I antigen,
cell fusion of the donor cells and recipient cells was ex-
cluded. PCR analysis using human and mouse specific
primers also omits the possibility of cell fusion. In a fur-
ther secondary transplant assay, HLA-ABC-negative cells
have in vivo differentiation capacity into human hepato-
cytes. These results indicate that donor-derived human
hepatocytes have only human genetic and immunological
properties, suggesting that cell fusion of donor SHED and
recipient hepatocytes in the hepatogenic process may be a
rare or nonexistent phenomenon in recipient CCl4-injured
mice. From another point of view, cell fusion between re-
cipient hepatocytes and hematopoietic stem cells might
lead to genetic instability and formation of cancer stem
cells [51]. Human MSCs exhibit a low tumorigenic poten-
tial in vivo [52] and in vitro [53]. The present findings in-
dicate that SHED may provide an attractive and safe
source for stem cell-based liver regeneration. However, a
long-term in vivo experiment will be necessary to assess
the safety and tumorigenic risk(s) after SHED transplant-
ation in damaged livers.
The present immunohistochemical findings suggest
that intrasplenically infused donor SHED are transported
into recipient liver through the portal vein system via
the splenic vein, and penetrated into CCl4-damaged
fibrous area via the interlobular portal veins. However,
the mechanism underlying in vivo homing and hepatic
potential of transplanted MSCs, including SHED, re-
mains unclear. In vivo homing and hepatic potential of
MSCs might be regulated by a microenvironment of
injured liver tissues. Liver contributes to a niche for
hematopoietic stem cells in the fetus [54] and in patients
with osteomyelofibrosis [55]. Hepatic stellate cells support
hematopoiesis in fetal livers [56], and activated hepatic
stellate cells release a factor associated with stem cell
homing and migration, C-X-C motif chemokine 12 [57],
and a factor promoting hepatocyte proliferation and dif-
ferentiation, HGF [58]. In addition, hepatic stellate cells
modulate a hepatogenic potential of bone marrow MSCs
[59]. These previous studies suggest that activated hepatic
stellate cells might function as a niche to modulate the
homing and hepatic differentiation of transplanted MSCs.
Further studies will be necessary to elucidate cellular andmolecular mechanism(s) responsible for in vivo homing
and hepatic potential of transplanted MSCs, including
SHED.
In this study, purified HLA-ABC-positive cells from
liver tissue of SHED-transplanted CCl4-treated mice
confirmed the expression of several characteristics as
human hepatocyte-like cells. The present secondary
transplantation into CCl4-treated mice analysis demon-
strates that purified HLA-ABC-positive cells express a
homing capacity and a treatment efficacy in CCl4-in-
jured mice, suggesting that in vivo-converted SHED-
derived hepatocytes may function as human hepato-
cytes. Chimeric human livers with more than 90 % hu-
man hepatocytes are successfully developed in murine
models [60, 61]. A recently reported novel tissue engin-
eering approach generated a transplantable recellular-
ized liver graft with human hepatocytes and MSCs
using xenogeneic decellularized livers [62, 63]. The
present in vivo serial transplantation assay demon-
strated that SHED-derived direct-converted hepatocytes
exhibit chimerism and therapeutic effect in CCl4-dam-
aged mouse livers. These results suggest that in vivo-
generated human hepatocyte-like cells derived from
donor SHED may provide an alternative source for
banking of human hepatocytes and development of
human chimeric livers in vivo and ex vivo.
Conclusion
In summary, this report provides a foundation for
SHED-based liver regenerative medicine. Further stud-
ies will be required to elucidate whether this practical
and unique approach can be applied clinically for pa-
tients with liver disorders, such as liver fibrosis, meta-
bolic diseases, or some coagulopathies.
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